The injections, which are therapeutically equivalent to Eloxatin from Sanofi-Aventis, received approval from the FDA for Sun Pharma’s abbreviated new drug application (ANDA).
Eloxatin is a registered trademark of Sanofi Aventis US, according to Caraco Pharmaceutical release. Teva Pharmaceutical Industries also sells a generic version of the drug, which is aimed at colon and rectal cancers.
Caraco said that it sells approximately $1.3bn worth of Oxaliplatin injections in the US.